Insmed Profit Margin 2006-2021 | INSM
Current and historical gross margin, operating margin and net profit margin for Insmed (INSM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Insmed net profit margin as of June 30, 2021 is -219.67%.
|Insmed Annual Profit Margins
|Insmed Quarterly Profit Margins
||Medical - Biomedical and Genetics
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.